Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Authors:
Open Access
- 14 April 2018
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 35 (8) , 1096-1104
Abstract
Aims: To assess the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes to identify the appropriate doses for further paediatric development.Methods: We conducted a single‐dose, open‐label, randomized, parallel‐group study with empagliflozin 5 mg, 10 mg and 25 mg in young people with Type 2 diabetes aged 10–17 years.Results: Of 39 participants screened, 27 were randomized and completed the study; their mean (± sd) age was 14.1±2.0 years and body weight was 96.7±23.5 kg. Compared with similar studies in adults with Type 2 diabetes, the maximum observed plasma concentrations were slightly lower with the 10‐mg and 25‐mg doses, and the area under the plasma concentration–time curve was slightly lower with the 10‐mg but slightly higher with the 25‐mg dose. The adjusted mean increases in urinary glucose excretion were 53 g/24 h (95% CI 32,74), 73 g/24 h (95% CI 52,94) and 87 g/24 h (95% CI 68,107), and the adjusted mean decreases in fasting plasma glucose were 0.9 mmol/l (95% CI –1.6,–0.1), 0.9 mmol/l (95% CI –1.7,–0.2) and 1.1 mmol/l (95% CI –1.8,–0.5) for the 5‐ 10‐ and 25‐mg doses, respectively. There were no serious adverse events and one investigator‐reported drug‐related event (dehydration).Conclusions: After a single oral dose of empagliflozin, adults and young people with Type 2 diabetes had similar exposure–response relationships after adjusting for significant covariates. These data support testing 10‐mg and/or 25‐mg doses of empagliflozin in an upcoming paediatric phase III Type 2 diabetes trial.(ClinicalTrials.gov registration no.: NCT02121483).Keywords
Funding Information
- Boehringer Ingelheim
This publication has 19 references indexed in Scilit:
- Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012New England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and HypertensionDiabetes Care, 2014
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 DiabetesDiabetes Care, 2014
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled TrialDiabetes Care, 2014
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2014
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitusJournal of Diabetes Investigation, 2013
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at BaselineThe Journal of Clinical Endocrinology & Metabolism, 2011